Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe: A Follow-up Physician Survey

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/40458
• EU PAS number:
  EUPAS30727
• Study ID:
  40458
• Official title and acronym:
  Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe: A Follow-up Physician Survey
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany

  Italy

  Spain

  United Kingdom
• Study description:
  The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians with recent aflibercept experience in a total of up to 5 European countries. Physicians from a physician panel will be invited to complete a brief web-based structured questionnaire regarding their knowledge of key safety information in the aflibercept educational materials.
• Study status:
  Finalised

Research institution and networks

Institutions

RTI Health Solutions (RTI-HS)

France

Spain

Sweden

United Kingdom

United Kingdom (Northern Ireland)

United States

Contact details

Bayer Clinical Trials BAYER AG

Study contact

[e-mail]

Bayer Clinical Trials BAYER AG

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 22/03/2019

Data collection

Planned: 01/10/2019

Actual: 08/10/2019

Date of final study report

Planned: 01/12/2020

Actual: 21/08/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Study protocol

Initial protocol

20285_Study Protocol_V2.0_2018-10-26_Redacted

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)